Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors

American Journal of Veterinary Research

Volumn 71, Issue 11, 2010, Pages 1354-1361

  Hahn, Kevin A ^a,p   Legendre, Alfred M ^b   Shaw, Neil G ^c   Phillips, Brenda ^d   Ogilvie, Gregory K ^e   Prescott, Deborah M ^f   Atwater, Stephen W ^g   Carreras, Janet K ^h   Lana, Susan E ⁱ   Ladue, Tracy ^j   Rusk, Anthony ^k   Kinet, Jean Pierre ^l   Dubreuil, Patrice ^m,n   Moussy, Alain ⁿ   Hermine, Olivier ^o  

^a GULF COAST VETERINARY SPECIALISTS   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Parc d'activités Mermoz   (United States)

^d Veterinary Specialty Hospital   (United States)

^e California Veterinary Specialists   (United States)

^f MedVet   (United States)

^g East Bay Veterinary Specialists   (United States)

^h Veterinary Cancer Associates PA   (United States)

ⁱ Department of Environmental and Radiological Health Sciences   (United States)

^j Southeast Veterinary Oncology   (United States)

^k Friendship Hospital for Animals   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

^m AIX MARSEILLE UNIVERSITY   (France)

ⁿ AB Science Société Anonyme   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p Hill's Pet Nutrition Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MASITINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DOG; DRUG EFFICACY; MASTOCYTOMA; NONHUMAN; OVERALL SURVIVAL; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; MAST-CELL SARCOMA; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; SURVIVORS; THIAZOLES; TIME FACTORS;

ANIMALIA; CANIS FAMILIARIS;

EID: 78149397178     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.11.1354     Document Type: Article

References (18)

1. Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008;6:1137-1145.
2. London CA, Kisseberth WC, Galli SJ, et al. Expression of stem cell factor receptor (c-kit) by the malignant mast cells from spontaneous canine mast cell tumours. J Comp Pathol 1996;115:399-414.
3. Qiu FH, Ray P, Brown K, et al. Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988;7:1003-1011.
4. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002;39:529-535.
5. Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009;4:e7258.
6. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-1309.
7. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
8. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
9. Machin D, Cheung YB, Parmar M. Survival analysis: a practical approach. 2nd ed. Chichester, England: John Wiley & Sons Inc, 2006.
10. London CA. A tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009;24:106-112.
11. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865.
12. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 2003;33:473-489.
13. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764.
14. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-378.
15. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
16. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-1411.
17. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
18. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.